Robin Rodgers, MD
Family Medicine · Cartersville, GANPI 1811958309
Payments from drug & device makers
Across 265 payments — averaging $16.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$543
- AstraZeneca$521
- GSK$518
- AbbVie$410
- Novo Nordisk$330
- Boehringer Ingelheim$217
- plus $2K from 30 others
What the payments were for
- Food & beverage$4,269100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 31 | $543 |
| AstraZeneca | 37 | $521 |
| GSK | 34 | $518 |
| AbbVie(2 entities) | 35 | $410 |
| Novo Nordisk | 22 | $330 |
| Boehringer Ingelheim | 12 | $217 |
| Novartis | 10 | $198 |
| Pfizer | 10 | $177 |
| Bayer | 6 | $133 |
| Merck | 8 | $129 |
| Lilly USA, LLC | 7 | $114 |
| Exact Sciences | 5 | $94 |
| Abbott | 5 | $89 |
| Eisai Inc. | 5 | $83 |
| Johnson & Johnson | 4 | $73 |
| Abiomed | 3 | $69 |
| Esperion Therapeutics, Inc. | 4 | $68 |
| Xeris Pharmaceuticals, Inc. | 4 | $67 |
| Shield Therapeutics Inc | 2 | $51 |
| Corcept Therapeutics | 2 | $41 |
| Biohaven Pharmaceuticals, Inc. | 2 | $36 |
| IBSA Pharma Inc. | 2 | $32 |
| Kowa Pharmaceuticals America, Inc. | 2 | $30 |
| Ultragenyx Pharmaceutical Inc. | 1 | $26 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $25 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $24 |
| Edwards Lifesciences | 1 | $22 |
| Astellas Pharma US Inc | 1 | $20 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| Scilex Pharmaceuticals Inc. | 1 | $17 |
| Linus Health, Inc. | 1 | $17 |
| Ironwood Pharmaceuticals, Inc | 1 | $17 |
| Antares Pharma, Inc. | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Heartflow, Inc. | 1 | $14 |
How this compares
$4,269 in reported general payments places this provider in the 80th percentile of 3,111 family medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 105 | $105,585 |
| FarxigaDapagliflozin Propanediol | 84 | $60,989 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 67 | $56,989 |
| OzempicSemaglutide | 58 | $53,081 |
| JanuviaSitagliptin Phosphate | 62 | $50,130 |
| RybelsusSemaglutide | 25 | $35,247 |
| KerendiaFinerenone | 32 | $26,732 |
| LinzessLinaclotide | 31 | $24,578 |
| XareltoRivaroxaban | 26 | $20,945 |
| MounjaroTirzepatide | 19 | $19,030 |
| TradjentaLinagliptin | 11 | $16,904 |
| Tresiba Flextouch U-100Insulin Degludec | 21 | $14,868 |
| EliquisApixaban | 21 | $13,329 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 15 | $10,086 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 521 | $9,314 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat | $217 | $132,575131 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $330 | $90,20594 claims |
| AstraZenecaFarxiga, Symbicort | $521 | $65,133100 claims |
| GSKTrelegy Ellipta | $518 | $56,98967 claims |
| MerckJanuvia | $129 | $50,13062 claims |
| BayerKerendia | $133 | $26,73232 claims |
| AbbVieLinzess | $410 | $24,57831 claims |
| Johnson & JohnsonXarelto | $73 | $20,94526 claims |
| Lilly USA, LLCMounjaro | $114 | $19,03019 claims |
| PfizerEliquis | $177 | $13,32921 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,111 family medicine providers in Georgia.
Other family medicine in Cartersville
- Joseph SurberColumbus$16.6M
- Angela RitterGainesville$15.8M
- Jeffrey KingsleyColumbus$8.1M
- Christopher OldfieldSavannah$6.4M
- Darrell MurrayAtlanta$3.9M
- Ben ThomasAtlanta$3.2M
- Debbie HaginsSavannah$2.1M
- Aziz PiraniLilburn$2.1M
- Nadia CameronAtlanta$2.1M
- John LentzSnellville$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.